Firmonertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), is widely used in treating NSCLC patients with EGFR mutations (Shi et al., 2022; Chen et al., 2023; Ding et al., 2024). Here, EGFR is linked to non-small cell lung carcinoma.